Platinum-based chemotherapeutic drugs are currently divided into three major categories, that is, three major generations: First, cisplatin, which is the most widely used platinum drug, has a strong broad-spectrum anti-cancer activity, mainly through the destruction of tumor cell DNA, inhibition of replication and induction of apoptosis, while playing an anti-tumor role. However, its toxic side effects are relatively large, and it is easy to produce hepatotoxicity, cardiotoxicity, neurotoxicity, ototoxicity and hematotoxicity, because these toxic side effects limit its clinical application. Secondly, carboplatin and nedaplatin, carboplatin has higher chemical stability, water solubility and stronger antitumor activity, it has lower toxicity compared to cisplatin, and the gastrointestinal reaction is not as strong as cisplatin, while its ototoxicity and neurotoxicity are rare. Therefore, carboplatin and nedaplatin are mainly used in patients with gynecological tumors or lung cancer. Thirdly, loplatin and oxaliplatin, etc. At present, the anti-cancer activity of loplatin is similar to that of cisplatin, but it has less nephrotoxicity and GI reactions than cisplatin, and it is also an optional drug for some tumor patients who are resistant to cisplatin. Loplatin is more efficient as a single agent in the treatment of GI tract tumors, and it has been widely used in gynecologic oncology. Oxaliplatin has no cross-resistance with cisplatin, and the toxic reactions of oxaliplatin are milder and well tolerated. At present, it has been widely used mainly in gastrointestinal tract tumors, and more oxaliplatin is used in esophageal cancer, gastric cancer and intestinal cancer.